Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1993-11-08
1995-04-25
Lone, Werren B.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514314, 544353, 544354, 544355, 546167, A61K 31495, A01N 4358
Patent
active
054099307
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to the inhibition of cell proliferation. More specifically, this invention relates to the use of bis mono- and/or bicyclic aryl and/or heteroaryl compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors.
Normal cellular reproduction is believed to be triggered by the exposure of the cellular substrate to one or more growth factors, examples of which are insulin, epidermal growth factor (EGF) and platelet-derived growth factor (PDGF). Such growth factor receptors are imbedded in and penetrate through the cellular membrane. The initiation of cellular reproduction is believed to occur when a growth factor binds to the corresponding receptor on the external surface of the cellular membrane. This growth factor-receptor binding alters the chemical characteristics of that portion of the receptor which exists within the cell and which functions as an enzyme to catalyze phosphorylation of either an intracellular substrate or the receptor itself, the latter being referred to as autophosphorylation. Examples of such phosphorylation enzymes include tyrosine kinases, which catalyze phosphorylation of tyrosine amino acid residues of substrate proteins.
Many disease states are characterized by the uncontrolled reproduction of cells. These disease states involve a variety of cell types and include disorders such as leukemia, cancer, psoriasis, inflammatory diseases, bone diseases, atherosclerosis and restenosis occuring subsequent to angioplastic procedures. The inhibition of tyrosine kinase is believed to have utility in the control of uncontrolled cellular reproduction, i.e., cellular proliferative disorders.
Initiation of autophosphorylation, i.e., phosphorylation of the growth factor receptor itself, and of the phosphorylation of a host of intracellular substrates are some of the biochemical events which are involved in mitogenesis and cell proliferation. Autophosphorylation of the insulin receptor and phosphorylation of substrate proteins by other receptors are the earliest identifiable biochemical hormonal responses.
Elimination of the protein tyrosine kinase (PTK) activity of the insulin receptor and of the epidermal growth factor (EGF) receptor by site-directed mutagenesis of the cellular genetic material which is responsible for generation of insulin and EGF results in the complete elimination of the receptor's biological activity. This is not particularly desirable because insulin is needed by the body to perform other biological functions which are not related to cell proliferation. Accordingly, compounds which inhibit the PTK portion of the EGF and/or PDGF receptor at concentrations less than the concentrations needed to inhibit the PTK portion of the insulin receptor could provide valuable agents for selective treatment of cell proliferation disorders.
REPORTED DEVELOPMENTS
It has been reported that the most potent inhibitors of EGF receptors inhibit EGF-induced proliferation of A431/clone 15 cells with little or no effect on the proliferation of such cells when induced by other growth factors. It has been reported also that erbstatin inhibits the autophosphorylation of the EGF receptor in membranes of A431 cells. Higher concentrations of erbstatin are required to inhibit cyclic adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase.
SUMMARY OF THE INVENTION
In accordance with the present invention, there is provided a method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration to a patient of an EGF and/or PDGF receptor inhibiting effective amount of a bis mono- and/or bicyclic aryl and/or heteroaryl compound exhibiting protein tyrosine kinase inhibition activity wherein each aryl and/or heteroaryl group is a ring system containing 0-4 hetero atoms, said compound being optionally substituted or polysubstituted.
Another aspect of the present invention relates to pharmaceutical compositions comp
REFERENCES:
patent: 4322420 (1982-03-01), Kabayoshi et al.
patent: 4464375 (1984-08-01), Kabayoshi et al.
patent: 4465686 (1984-08-01), Lesher et al.
patent: 4599423 (1986-07-01), Lesher et al.
patent: 4661499 (1987-04-01), Young et al.
Maquire Martin P.
Myers Michael R.
Persons Paul E.
Spada Alfred P.
Lone Werren B.
Nicholsen James A.
Parker III Raymond S.
Rhone-Poulenc Rorer Pharmaceuticals Inc.
Savitzky Martin F.
LandOfFree
Bis mono- and bicyclic aryl and heteroaryl compounds which inhib does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bis mono- and bicyclic aryl and heteroaryl compounds which inhib, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bis mono- and bicyclic aryl and heteroaryl compounds which inhib will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1567922